GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jianmin Pharmaceutical Group Co 600976.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

27.61

-1.18%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jianmin Pharmaceutical Group Co

Its shares trade on Shanghai under the ticker 600976.SS. It has been listed since 19 April 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.35bn and net income of CN¥359.8m. At that date it held total assets of CN¥4.53bn and shareholders' equity of CN¥2.66bn.

Jianmin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, wholesale and retail of pharmaceutical products. The company is headquartered in Wuhan, Hubei. The company went IPO on 2004-04-19. The firm operates its businesses through two segments, including Pharmaceutical Industry and Pharmaceutical Business. The Pharmaceutical Industry segment is engaged in the research and development and manufacture of pharmaceuticals. Its products are mainly applied in children, women and the elderly, among others. The Pharmaceutical Business segment is engaged in the wholesale and retailing of pharmaceuticals. Its products include traditional Chinese medicine, Western medicine, health products, medical equipment and chemical agents. The company distributes its products mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Apr 2004
Employees
2,248
Website
whjm.com ↗

Leadership

Pay as last reported

  • Mr. Qin HeChairman of the BoardCN¥1.0m
  • Mr. Jun WangPresident, DirectorCN¥710,800
  • Mr. Liang XuVice Chairman of the BoardCN¥60,000
  • Mr. Zhaoyang ChengChief Financial OfficerCN¥490,500
  • Mr. Zhenbo HuVice President, Director
  • Mr. Zhongjiang BuVice PresidentCN¥519,600
  • Mr. Kai GaoVice PresidentCN¥547,800
  • Mr. Zhijun HuangVice PresidentCN¥482,200
  • Mr. Xuejun PeiVice PresidentCN¥489,200
  • Mr. Jie ZhouSecretary of the BoardCN¥287,700
  • Ms. Rong PeiDirectorCN¥60,000
  • Mr. Siyang WangDirectorCN¥60,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Wuhan, Hubei with 2,248 employees
  • Operates through two segments: Pharmaceutical Industry and Pharmaceutical Business
  • Products target children, women, and the elderly

Weaknesses

  • No mention of international market presence
  • Reliance on domestic market distribution
  • No information on R&D investment or product innovation

Opportunities

  • Expansion into international markets for pharmaceutical products
  • Growth potential in traditional Chinese medicine and Western medicine segments
  • Increasing demand for health products and medical equipment

Threats

  • Dependence on domestic market may limit growth
  • Competition in pharmaceutical industry could affect market share
  • No information on regulatory challenges or market saturation

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.